Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.17 | N/A | -82.23% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.17 | N/A | -82.23% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about current market conditions. They highlighted ongoing efforts to improve performance despite setbacks.
Management acknowledged the challenges faced this quarter.
They emphasized the importance of strategic initiatives moving forward.
The earnings report indicates that Alkermes is struggling with profitability, as evidenced by the significant EPS miss. The stock reaction reflects investor disappointment, leading to a decline of nearly 13%. Without guidance, uncertainty remains about the company's future performance and strategic direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KIMBERLY CLARK CORP
Apr 22, 2019